GERALDIN ROMIS: Open Payments
NPI 1053819961 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,610 in 62 payments from 13 companies in 2025. Trend: 2023 $670 · 2024 $1,229 · 2025 $1,610
Food & beverage: $1,429Education: $181
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $479 |
| Incyte Corporation | 9 | $245 |
| Janssen Biotech, Inc. | 10 | $223 |
| Organon LLC | 7 | $131 |
| GENZYME CORPORATION | 4 | $126 |
| ABBVIE INC. | 5 | $105 |
| Lilly USA, LLC | 3 | $90 |
| Galderma Laboratories, L.P. | 2 | $66 |
| LEO Pharma Inc. | 3 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
Products named: DUPIXENT, OPZELURA, TREMFYA, TALTZ, SKYRIZI, NEMLUVIO, ADBRY, RINVOQ.
Industry payments across CA — which companies pay providers there.
